Last reviewed · How we verify
"Metformin" and "Mitiglinide"
Metformin reduces hepatic glucose production and improves insulin sensitivity, while mitiglinide stimulates pancreatic beta cells to release insulin in response to meals.
Metformin reduces hepatic glucose production and improves insulin sensitivity, while mitiglinide stimulates pancreatic beta cells to release insulin in response to meals. Used for Type 2 diabetes mellitus.
At a glance
| Generic name | "Metformin" and "Mitiglinide" |
|---|---|
| Sponsor | Third Affiliated Hospital of Third Military Medical University |
| Drug class | Antidiabetic combination (biguanide + meglitinide) |
| Target | Metformin: AMP-activated protein kinase (AMPK); Mitiglinide: ATP-sensitive potassium channel (KATP) |
| Modality | Small molecule |
| Therapeutic area | Endocrinology / Diabetes |
| Phase | FDA-approved |
Mechanism of action
Metformin is a biguanide that decreases gluconeogenesis and glycogenolysis in the liver and increases peripheral glucose uptake and utilization. Mitiglinide is a meglitinide that binds to ATP-sensitive potassium channels on pancreatic beta cells, triggering rapid insulin secretion. Together, they address both insulin resistance and beta cell dysfunction in type 2 diabetes.
Approved indications
- Type 2 diabetes mellitus
Common side effects
- Gastrointestinal disturbance (nausea, diarrhea, abdominal discomfort)
- Hypoglycemia
- Headache
- Lactic acidosis (rare, metformin-related)
Key clinical trials
- Omarigliptin (MK-3102) Clinical Trial - Add-on to Oral Antihyperglycemic Agent Study in Japanese Participants With Type 2 Diabetes Mellitus (MK-3102-015) (PHASE3)
- Effects of Incretin on the Blood Pressure and Lipid in Patients With Overweight or Obese Diabetes (PHASE4)
- Pharmacokinetics of Mitiglinide and Metformin in Free Combination and Fixed-dose Combination in Healthy Male Subjects. (PHASE1)
- Effect of Combination of Mitiglinide and Metformin on Glycemic Control in Patients With Type 2 Diabetes Mellitus (PHASE3)
- Mitiglinide in Combination With Metformin vs. Metformin Alone in Patients With Type 2 Diabetes Mellitus (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: